This strategy represents a novel approach to inducing host responses against tumors, as evidenced by the survival rate increase observed in melanoma patients [90,91] and lung cancer patients [92,93] treated with a combination of PD1 and CTLA-4 inhibition. Here, CTLA4 is linked to melanoma.